Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. - Test2 - elhamkhani - TriplyDB

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.

http://www.wikidata.org/entity/Q33997756

about

Pharmacology of manipulating lean body mass Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia.Novel treatments for cancer cachexia.A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.Treatment of cachexia in oncology A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project.Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trial Optimal management of cancer anorexia-cachexia syndrome.Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.Pancreatic cancer cachexia: a review of mechanisms and therapeutics.Cancer cachexia, mechanism and treatment Plasma phospholipid PUFAs are associated with greater muscle and knee extension strength but not with changes in muscle parameters in older adults.Nutritional interventions for cancer-induced cachexia Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT.Cancer symptom control trials: how may we advance this field?n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.Marine polyunsaturated fatty acids and cancer therapy Pharmacological options for advanced cancer patients with loss of appetite and weight.Cancer cachexia prevention via physical exercise: molecular mechanisms.Emerging drugs for cancer cachexia.Exercise and nutrition interventions in advanced lung cancer: a systematic review.Fatigue in palliative care patients -- an EAPC approach.Inflammatory burden and amino acid metabolism in cancer cachexia.Muscle function and omega-3 fatty acids in the prediction of lean body mass after breast cancer treatment.The assessment and impact of sarcopenia in lung cancer: a systematic literature review Update on emerging drugs for cancer cachexia.Nutrition aspects of lung cancer.Nutrition support and dietary interventions for patients with lung cancer: current insights.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Nutritional support and quality of life in cancer patients undergoing palliative care.Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies.Weight changes correlate with alterations in subjective physical function in advanced cancer patients referred to a specialized nutrition and rehabilitation team.The role of inflammatory pathways in cancer-associated cachexia and radiation resistance.Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.

P2860

Q26824503-3391768B-7557-434B-9ADD-73A948B57561 Q26827510-7CD12C1E-4C3C-4F60-83FD-C5E7F183FBDE Q28483912-5FE3D9A0-41EF-4A53-BBEE-E05825FAB809 Q33755930-59F2119F-F211-4D6A-A6D8-10EB0F7F9405 Q33880985-D5221573-1821-4CB7-A1A4-61B98A8052D1 Q34005616-1A1B9896-A8CB-41F7-B065-2FE5DFBA3DE4 Q34082057-5994B97D-781F-4BF8-8A2E-327C26302011 Q34158188-FCE44EC3-1B45-49C9-BA3F-C6DDCD3D99D1 Q34210506-625648B1-9BEC-48B8-B9D2-7E96637005D8 Q34354878-D60B28D9-EE1D-492B-BAAA-E19BF09E745C Q34417908-C1BC6103-9C6F-4003-8CC7-B8E6CB77450E Q34583647-DD75CB2C-3C50-4EDC-8385-5AEB0D084B0C Q34660312-143A337A-07C0-4D44-8190-5AE1D3EF24B8 Q34669440-9AB007D8-D10C-4C71-A1FF-EA7C98723BCA Q34684182-D9A8D2A3-70FF-47F7-B8EB-DB2567803048 Q35019743-B6832A1B-A584-44D9-A131-3A0B68E440AB Q35053606-573DA3D6-6B3A-41A7-A864-FEAD18F50D8B Q35583902-9452FB51-CFDE-4238-95A4-22A862434885 Q35708619-80349A6D-EAF1-424E-9885-8B897EF40B81 Q35828425-E4BA0048-F993-4BC8-BA50-0B6329C930E1 Q35855357-141FAAD3-278E-475C-85E8-7BC4C689DD36 Q36131716-2A0BDE99-71BA-4C49-8CB9-6A70B047B423 Q36671846-59DA7E99-84BC-4F74-AFA9-6B5E9718B3BC Q36828134-DB83761D-A6D0-466B-B79B-650745901886 Q36934986-A5C5CCF3-AE3F-43C7-9FA2-81C1517B4054 Q36989913-470FED08-D791-4551-93D7-CD4B304CDF67 Q37056898-3F2FFD88-0B77-4B5F-B823-C7AA9A5FD152 Q37063833-36E510BF-AB67-49EB-853C-BED99637CF7D Q37341440-5072396F-9268-4691-BB3D-AE7AC31E10C1 Q37439648-706FE28D-E518-4F91-805D-DBA6153381E1 Q37516578-5421A107-27E8-4C13-90BD-B86F302B7914 Q37622253-2902D967-38BB-4FA7-8D0C-C8DD7BC95CB1 Q37643139-63FA40CC-A34E-4401-B153-138D856C0B95 Q37643539-BC73934B-5724-440F-AB00-85C34E298BDB Q37974894-898476FC-22A7-456D-A0A5-9E88C8BAE206 Q38009042-1B44D51B-021C-45B8-AD1F-F5E347FE80B0 Q38010559-B48B6CA5-7193-4FCA-9D75-E634E4612FFF Q38084604-4645FEEC-0907-46DE-864E-A2E7452C3DE0 Q38115997-5A617652-352C-4253-B685-D6E832C55A49 Q38215557-0A702580-E460-4E68-8572-81D84C7CB3BC

P2860

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.

http://www.wikidata.org/entity/Q33997756

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Double-blind, placebo-controll ...... patients with cancer cachexia.

@ast

Double-blind, placebo-controll ...... patients with cancer cachexia.

@en

type

label

Double-blind, placebo-controll ...... patients with cancer cachexia.

@ast

Double-blind, placebo-controll ...... patients with cancer cachexia.

@en

prefLabel

Double-blind, placebo-controll ...... patients with cancer cachexia.

@ast

Double-blind, placebo-controll ...... patients with cancer cachexia.

@en

P1433

Q33997756-08072360-5660-4CF7-9279-FFC5157057F1

P1476

Q33997756-8D6060A9-770D-4549-93CA-E42B634783E6

P2093

Q33997756-21BC355D-C9ED-407F-AFF8-9B18AAF51355

Q33997756-8624EB65-B9E8-4403-B408-D7159E3B3217

Q33997756-BFA092AA-C3A1-4D5F-BA5B-340B8E6A48A1

Q33997756-D84E78E1-2A96-422D-89B9-0729AD1781CD

Q33997756-E1539175-30DF-4E38-9FE8-826C11661FD4

P304

Q33997756-9148C5C8-375C-4EA8-8B12-603E4EFCCA96

P31

Q33997756-51293B56-CD3C-4F3E-BCAD-B9B12DF22E33

P356

Q33997756-B551FC80-E5EF-4D65-B43E-D28C4DC70C17

P407

Q33997756-AE1502F4-9FC1-474A-88E2-1151C6B9435F

P433

Q33997756-FF1F15EB-2C92-4EE7-9028-F65B53377764

P478

Q33997756-516A3469-AC92-4F66-BCB1-7AACC3B6691B

P50

Q33997756-352BC0B4-CD12-4C1C-994E-319CC9D1B42B

Q33997756-E4439CC9-4031-42A5-BCF3-CD4EC789C5B9

P577

Q33997756-447B6EE8-AB68-42EA-8CF9-008C80D5D233

P698

Q33997756-90C736D6-65DF-4CDA-9D9B-1AB76332B4AA

P921

Q33997756-D14DBC96-A7D7-4570-BA6F-52E9CD3D0F2C

P356

JCO.2005.04.5724

P1433

Journal of Clinical Oncology

P1476

Double-blind, placebo-controll ...... patients with cancer cachexia.

@en

P2093

Alastair G Moses

http://www.w3.org/2001/XMLSchema#string

Gillian S Taylor

http://www.w3.org/2001/XMLSchema#string

Kenneth C H Fearon

http://www.w3.org/2001/XMLSchema#string

Matthew D Barber

http://www.w3.org/2001/XMLSchema#string

Michael J Tisdale

http://www.w3.org/2001/XMLSchema#string

P304

3401-3407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.04.5724

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16849754

http://www.w3.org/2001/XMLSchema#string

P921